RAC1 and melanoma: One study found that in melanoma cells, lidocaine and ropivacaine, but not bupivacaine, decreased Ras, RhoA, and Rac1 expression, and augmented the antimigratory, antiproliferative and pro-apoptotic effects of the chemotherapeutic agents vemurafenib and dacarbazine when used in combination.56